Imunon agrees to sell ThermoDox rights to VoxelDox Therapeutics

PUBT · 1d ago
Imunon agrees to sell ThermoDox rights to VoxelDox Therapeutics
  • Imunon agreed to sell its rights to ThermoDox, a heat-activated liposomal formulation of doxorubicin, to VoxelDox Therapeutics.
  • Consideration includes an approximately 4.76% equity interest in VoxelDox and up to $16.5 million in development and sales-based milestone payments.
  • Tiered royalties range from 3.5% to 6% of net sales of ThermoDox-related products, if approved.
  • Closing depends on VoxelDox completing $2.5 million in financing to support a Phase 1 glioblastoma trial.
  • The sale preserves potential economic participation while focusing resources on the pivotal Phase 3 OVATION 3 trial of IMNN-001 in advanced ovarian cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610210815PRIMZONEFULLFEED9849977) on October 21, 2026, and is solely responsible for the information contained therein.